Table 1.

Characteristics of 42 Patients With Intermediate Grade and Immunoblastic Lymphoma (Group I)

%
 
42 
Age (yr) 
Median 33.5 
Range (16.5-56) 
M:F 30:12 
Histology FLC 6, DM 5, DLC 21, IBL 10 
Stage 
II 12 
III 19 
IV 29 69 
ECOG 
PS1 12 
PS2 18 43 
PS3 19 45 
LDH 
Elevated 35 83 
Normal 17 
Bulky DS ≥8 cm 
Yes 36 86 
No 14 
Extranodal sites 
Yes 33 79 
≥2 sites 16 38 
Age-adjusted IPI risk 
High 25 60 
High-intermediate 17 40 
Prior chemotherapy CHOP 19, CHOP-Bleo 1, MACOP-B 7, M/m BACOD 8, ProMACE-CytoBOM 4, ProMACE-MOPP 1, Vanderbilt 1, VACOP-B 1  
Median no. of cycles 
(range) 6 (3-10) 
Prior RT 12 
Status at BMT 
1 CR 32 76 
1 PR 10 24 
%
 
42 
Age (yr) 
Median 33.5 
Range (16.5-56) 
M:F 30:12 
Histology FLC 6, DM 5, DLC 21, IBL 10 
Stage 
II 12 
III 19 
IV 29 69 
ECOG 
PS1 12 
PS2 18 43 
PS3 19 45 
LDH 
Elevated 35 83 
Normal 17 
Bulky DS ≥8 cm 
Yes 36 86 
No 14 
Extranodal sites 
Yes 33 79 
≥2 sites 16 38 
Age-adjusted IPI risk 
High 25 60 
High-intermediate 17 40 
Prior chemotherapy CHOP 19, CHOP-Bleo 1, MACOP-B 7, M/m BACOD 8, ProMACE-CytoBOM 4, ProMACE-MOPP 1, Vanderbilt 1, VACOP-B 1  
Median no. of cycles 
(range) 6 (3-10) 
Prior RT 12 
Status at BMT 
1 CR 32 76 
1 PR 10 24 

Abbreviations: FLC, follicular large cell; DM, diffuse mixed; DLC, diffuse large cell; IBL, immunoblastic lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP-Bleo, CHOP + Bleomycin; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; M/m BACOD, methotrexate, Bleomycin, cyclophosphamide, vincristine, dexamethasone, Bleomycin; ProMACE-cyto BOM, cyclophosphamide, doxorubicin, Etoposide, cytorabine, Bleomycin, vincristine, prednisone; ProMACE-MOPP, ProMACE + Nitrogen Mustard, vincristine, prednisone, and procarbazine; Vanderbilt, cyclophosphamide, Etoposide, vincristine, Bleomycin, methotrexate, Doxorubicin, prednisone; VACOP-B, etoposide, adriamycin, oncovin, prednisone, and bleomycin.

Close Modal

or Create an Account

Close Modal
Close Modal